Clinical and laboratory characteristics of patients with cardiopulmonary comorbidence

Authors

  • Maryna Kochuieva Kharkiv Medical Academy of Postgraduate Education Amosova str., 58, Kharkiv, Ukraine, 61176, Ukraine
  • Hanna Tymchenko Kharkiv Medical Academy of Postgraduate Education Amosova str., 58, Kharkiv, Ukraine, 61176, Ukraine
  • Yulia Zaikina Kharkiv Medical Academy of Postgraduate Education Amosova str., 58, Kharkiv, Ukraine, 61176, Ukraine

DOI:

https://doi.org/10.15587/2519-4798.2020.192719

Keywords:

COPD, asthma COPD overlap, AH, systemic inflammation, CRP, IL-6, IL-8, TNF-α

Abstract

Comorbidity of bronchial obstructive diseases and arterial hypertension (AH) is an important medico-social problem due to the increased incidence, the severity of complications, the tendency to increase mortality and disability of patients. However, the clinical characteristics and role of the major markers of inflammation in the pathogenesis of conditions such as chronic obstructive pulmonary disease (COPD) and asthma-COPD overlap (ACO) against AH and their impact on the course of the disease remain poorly understood.

The aim of the study is to study the main clinical and laboratory parameters of patients with ACO and COPD with concomitant AH compared with each other and patients with isolated AH and with ACO without AH.

Materials and methods. To participate in the study, we selected 100 patients with ACO on the background of AH, 30 patients with ACO without AH, 30 patients with COPD on the background of AH, 30 patients with AH. Examination of patients included: clinical methods - analysis of complaints and anamnesis of patients, standard clinical examination with measurement of blood pressure and heart rate, anthropometric study with the determination of body mass index (BMI), spirometric study with a test for reversibility of bronchial obstruction, the concentration of interleukin 6 (IL-6), interleukin 8 (IL-8), tumor necrosis factor α (TNF-α) and C-reactive proteine (CRP) in serum were determined by enzyme immunoassay.

Results. Patients of the surveyed groups did not differ significantly in age and gender composition. There were no significant differences in smoking status and major indicators of respiratory function in the ACO and COPD groups, unlike the AH group. However, the FEV1 increase after bronchodilator inhalation was significantly higher in the ACO groups than in the COPD group and only AH. No significant differences were found between the study groups on TNF-α. At the same time, the group of patients with ACO on the background of AH was significantly different from the group of only ACO, COPD with AH and only AH in terms of CRP and IL-6; for IL-8 there was a significant difference compared with the groups with ACO and COPD with AH, and there were no significant differences with the AH group.

Conclusions. The less prolonged exposure of the smoking factor with the background of bronchial asthma leads to pronounced changes in respiratory function, similar to changes in COPD with greater exposure to smoking. ACO patients have a better reversal of bronchial obstruction in response to bronchodilators than patients with COPD, which may indicate a potential better response of this group of patients to bronchodilator treatment. The course of ACO on the background of AH is accompanied by more pronounced chronic inflammation

Author Biographies

Maryna Kochuieva, Kharkiv Medical Academy of Postgraduate Education Amosova str., 58, Kharkiv, Ukraine, 61176

MD, Professor

Department of Phthisiology, Pulmonology and Family Medicine

Hanna Tymchenko, Kharkiv Medical Academy of Postgraduate Education Amosova str., 58, Kharkiv, Ukraine, 61176

Postgraduate Student

Department of Phthisiology, Pulmonology and Family Medicine

Yulia Zaikina, Kharkiv Medical Academy of Postgraduate Education Amosova str., 58, Kharkiv, Ukraine, 61176

Postgraduate Student

Department of Phthisiology, Pulmonology and Family Medicine

References

  1. Projections of mortality and causes of death, 2015 and 2030. (2018). Available at: https://www.who.int/healthinfo/global_burden_disease/projections2015_2030/en/
  2. Non communicable diseases. Available at: https://www.who.int/en/news-room/fact-sheets/detail/noncommunicable-diseases
  3. Kumbhare, S., Pleasants, R., Ohar, J. A., Strange, C. (2016). Characteristics and Prevalence of Asthma/Chronic Obstructive Pulmonary Disease Overlap in the United States. Annals of the American Thoracic Society, 13 (6), 803–810. doi: http://doi.org/10.1513/annalsats.201508-554oc
  4. Diagnosis and initial treatment of asthma, copd and asthma-copd overlap (2017). Available at: https://ginasthma.org/wp-content/uploads/2019/11/GINA-GOLD-2017-overlap-pocket-guide-wms-2017-ACO.pdf
  5. Bujarski, S., Parulekar, A. D., Sharafkhaneh, A., Hanania, N. A. (2015). The Asthma COPD Overlap Syndrome (ACOS). Current Allergy and Asthma Reports, 15 (3). doi: http://doi.org/10.1007/s11882-014-0509-6
  6. Gerhardsson de Verdier, M., Andersson, M., Kern, D. M., Zhou, S., Tunceli, O. (2015). Asthma and Chronic Obstructive Pulmonary Disease Overlap Syndrome: Doubled Costs Compared with Patients with Asthma Alone. Value in Health, 18 (6), 759–766. doi: http://doi.org/10.1016/j.jval.2015.04.010
  7. Tinetti, M. E., Fried, T. R., Boyd, C. M. (2012). Designing Health Care for the Most Common Chronic Condition – Multimorbidity. JAMA, 307 (23). doi: http://doi.org/10.1001/jama.2012.5265
  8. Yeh, J.-J., Wei, Y.-F., Lin, C.-L., Hsu, W.-H. (2017). Association of asthma–chronic obstructive pulmonary disease overlap syndrome with coronary artery disease, cardiac dysrhythmia and heart failure: a population-based retrospective cohort study. BMJ Open, 7 (10), e017657. doi: http://doi.org/10.1136/bmjopen-2017-017657
  9. De Miguel-Díez, J., Chancafe Morgan, Jimenez-Garcia. (2013). The association between COPD and heart failure risk: a review. International Journal of Chronic Obstructive Pulmonary Disease, 305. doi: http://doi.org/10.2147/copd.s31236
  10. Woodruff, P. G., van den Berge, M., Boucher, R. C., Brightling, C., Burchard, E. G., Christenson, S. A. et. al. (2017). American Thoracic Society/National Heart, Lung, and Blood Institute Asthma–Chronic Obstructive Pulmonary Disease Overlap Workshop Report. American Journal of Respiratory and Critical Care Medicine, 196 (3), 375–381. doi: http://doi.org/10.1164/rccm.201705-0973ws
  11. Miravitlles, M., Alvarez-Gutierrez, F. J., Calle, M., Casanova, C., Cosio, B. G., López-Viña, A. et. al. (2017). Algorithm for identification of asthma–COPD overlap: consensus between the Spanish COPD and asthma guidelines. European Respiratory Journal, 49 (5), 1700068. doi: http://doi.org/10.1183/13993003.00068-2017
  12. Gold Reports for Personal Use – Global Initiative for Chronic Obstructive Lung Disease. Available at: https://goldcopd.org/gold-reports/
  13. Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M. et. al. (2018). 2018 ESC/ESH Guidelines for the management of arterial hypertension. Journal of Hypertension, 36 (10), 1953–2041. doi: http://doi.org/10.1097/hjh.0000000000001940
  14. ATS/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005 (2005). American Journal of Respiratory and Critical Care Medicine, 171 (8), 912–930. doi: http://doi.org/10.1164/rccm.200406-710st
  15. Gibson, P. G., Simpson, J. L. (2009). The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax, 64 (8), 728–735. doi: http://doi.org/10.1136/thx.2008.108027
  16. Kauppi, P., Kupiainen, H., Lindqvist, A., Tammilehto, L., Kilpeläinen, M., Kinnula, V. L. et. al. (2011). Overlap Syndrome of Asthma and COPD Predicts Low Quality of Life. Journal of Asthma, 48 (3), 279–285. doi: http://doi.org/10.3109/02770903.2011.555576
  17. Miravitlles, M., Soriano, J. B., Ancochea, J., Muñoz, L., Duran-Tauleria, E., Sánchez, G. et. al. (2013). Characterisation of the overlap COPD–asthma phenotype. Focus on physical activity and health status. Respiratory Medicine, 107 (7), 1053–1060. doi:10.1016/j.rmed.2013.03.007
  18. Fujimoto, K., Komatsu, Fujimoto, K., Hanaoka, M., Kubo, K. (2012). Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma. International Journal of Chronic Obstructive Pulmonary Disease, 283. doi: http://doi.org/10.2147/copd.s30651
  19. Menezes, A. M. B., Montes de Oca, M., Pérez-Padilla, R., Nadeau, G., Wehrmeister, F. C., Lopez-Varela, M. V. et. al. (2014). Increased Risk of Exacerbation and Hospitalization in Subjects With an Overlap Phenotype. Chest, 145 (2), 297–304. doi: http://doi.org/10.1378/chest.13-0622
  20. De Martinis, M., Franceschi, C., Monti, D., Ginaldi, L. (2005). Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Letters, 579 (10), 2035–2039. doi: http://doi.org/10.1016/j.febslet.2005.02.055
  21. Fu, J., McDonald, V. M., Gibson, P. G., Simpson, J. L. (2014). Systemic Inflammation in Older Adults With Asthma-COPD Overlap Syndrome. Allergy, Asthma & Immunology Research, 6 (4), 316–324. doi: http://doi.org/10.4168/aair.2014.6.4.316
  22. Mattson, D. L., Lund, H., Guo, C., Rudemiller, N., Geurts, A. M., Jacob, H. (2013). Genetic mutation of recombination activating gene 1 in Dahl salt-sensitive rats attenuates hypertension and renal damage. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 304 (6), R407–R414. doi: http://doi.org/10.1152/ajpregu.00304.2012
  23. Srivastava, K., Narang, R., Bhatia, J., Saluja, D. (2016). Expression of Heat Shock Protein 70 Gene and Its Correlation with Inflammatory Markers in Essential Hypertension. PLOS ONE, 11 (3), e0151060. doi: http://doi.org/10.1371/journal.pone.0151060

Downloads

Published

2019-01-30

How to Cite

Kochuieva, M., Tymchenko, H., & Zaikina, Y. (2019). Clinical and laboratory characteristics of patients with cardiopulmonary comorbidence. ScienceRise: Medical Science, (1 (34), 29–35. https://doi.org/10.15587/2519-4798.2020.192719

Issue

No. 1 (34) (2020)

Section

Medical Science

License

Copyright (c) 2020 Maryna Kochuieva, Hanna Tymchenko, Yulia Zaikina

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.

Authors, who are published in this journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.

 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.